Heat Biologics Appoints Two New Board Members
This article was originally published in Scrip
Heat Biologics, Inc., a cancer immunotherapy company, has appointed Holbrook Kohrt and Kapil Dhingra to its scientific and clinical advisory board. Kohrt is currently assistant professor of medicine, division of oncology at the Stanford University of Medicine, CA, and is also a board certified medical oncologist and internist there. Most recently, Dhingra held various management positions at Roche Pharmaceuticals, including vice-president, head of oncology and disease leadership team and head of oncology clinical development. He was also involved in the expansion of Roche Oncology. Prior to this Dhingra was senior clinical research physician at Eli Lilly and is currently managing member and founder of the healthcare firm, KAPital Consulting.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.